Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
520 E 70th St. Starr 341
New York, NY 10021Phone+1 646-962-2700Fax+1 646-962-0115
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2010 - 2013
- University of Alabama Medical CenterResidency, Internal Medicine, 2007 - 2010
- University of Miami Leonard M. Miller School of MedicineClass of 2007
Certifications & Licensure
- NY State Medical License 2010 - 2026
- GA State Medical License 2023 - 2025
- AL State Medical License 2009 - 2010
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing One-lung Ventilation for Lung Surgery Start of enrollment: 2012 Feb 01
Publications & Presentations
PubMed
- 20 citationsNorth American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati
Blood. 2023-02-09 - 47 citationsOlutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.Justin M Watts, Maria R Baer, Jay Yang, Thomas Prebet, Sangmin Lee
The Lancet. Haematology. 2023-01-01 - 10 citationsOral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents.Sangmin Lee, Sanjay Mohan, Jessica Knupp, Kamal Chamoun, Adrienne de Jonge
Journal of Hematology & Oncology. 2022-08-03
Journal Articles
- Somatic Mutations Precede Acute Myeloid Leukemia Years Before DiagnosisSangmin Lee, Pinkal Desai, Gail J Roboz, Ellen K Ritchie, Nature
Abstracts/Posters
- Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...Sangmin Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative NeoplasmsSangmin Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory MyelofibrosisSangmin Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive Chemotherapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Combinations of Modifiable Lifestyle Behaviours in Relation to Colorectal Cancer Risk in Alberta’s Tomorrow ProjectNovember 25th, 2020
- Debate: CML Patients with Molecular Response Should Stop Taking TKIsJanuary 1st, 2020
- Optimizing Care in Patients with Chronic Myelogenous LeukemiaNovember 20th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: